Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL versus FORADIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL versus FORADIL.
CHOLEDYL vs FORADIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular cAMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator